CLINICAL TRIALS PROFILE FOR JEMPERLI
✉ Email this page to a colleague
All Clinical Trials for JEMPERLI
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04926324 ↗ | A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers | Not yet recruiting | GlaxoSmithKline | Phase 1/Phase 2 | 2021-12-31 | This clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as well as patient reported outcome measures. |
NCT04926324 ↗ | A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers | Not yet recruiting | Joseph Caster, Ph.D., M.D. | Phase 1/Phase 2 | 2021-12-31 | This clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as well as patient reported outcome measures. |
NCT05526989 ↗ | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | Not yet recruiting | GlaxoSmithKline | Phase 2 | 2022-09-15 | The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer. |
NCT05526989 ↗ | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | Not yet recruiting | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | 2022-09-15 | The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer. |
NCT05870761 ↗ | Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma | Not yet recruiting | Casey Cosgrove | Phase 2 | 2023-06-30 | This phase II trial tests how well niraparib and dostarlimab work in treating patients with uterine serous carcinoma that has come back (after a period of improvement) (recurrent) and remains despite treatment (persistent). Niraparib belongs to a class of drugs called PARP inhibitors that prevent cancer cells from growing. Dostarlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Dostarlimab belongs to a class of drugs called PD-1 inhibitors that uses the patient's own immune system to treat cancer (immuno-therapy). Giving niraparib and dostarlimab may work better in treating patients with uterine serous carcinoma. |
NCT06023862 ↗ | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | Recruiting | Yonsei University | Phase 2 | 2024-01-22 | Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma. 198 subjects will be enrolled in this study and will be assigned to three groups in a 1:1:1 ratio. 1. Group A: Dostarlimab monotherapy - First 3 cycles: Dostalimab 500mg every 3 weeks, IV - 4 cycles ~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV 2. Group B: Dostarlimab + Bevacizumab combination therapy - First 3 cycles: Dostalimab 500mg every 3 weeks, IV - 4 cycles ~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV - Bevacizumab administered IV at 15 mg/kg every 3 weeks until disease progression or unacceptable toxicity 3. Group C: General chemotherapy (one of Pegylated liposomal doxorubicin, Doxorubicin, Paclitaxel, and Gemcitabine) |
NCT06059495 ↗ | Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study | Recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 2 | 2023-12-18 | This phase II study will evaluate dostarlimab with a watch-and-wait approach for patients with localized mismatch repair deficiency (dMMR)/microsatellite instability (MSI) gastric or oeso-gastric junction adenocarcinoma. The goal of the study is to determine whether the surgery could be avoided in patients with localized dMMR/MSI-H gastric/OGJ adenocarcinoma with complete response at endoscopy and biopsies free of tumoral cells after treatment with dostarlimab, with a watch-and-wait approaches. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for JEMPERLI
Condition Name
Clinical Trial Locations for JEMPERLI
Trials by Country
Clinical Trial Progress for JEMPERLI
Clinical Trial Phase
Clinical Trial Sponsors for JEMPERLI
Sponsor Name